Author
Listed:
- Matthew S. Block
(Mayo Clinic)
- Allan B. Dietz
(Mayo Clinic)
- Michael P. Gustafson
(Mayo Clinic)
- Kimberly R. Kalli
(Mayo Clinic)
- Courtney L. Erskine
(Mayo Clinic)
- Bahaaeldin Youssef
(Mayo Clinic)
- Geraldine V. Vijay
(Mayo Clinic)
- Jacob B. Allred
(Mayo Clinic)
- Kevin D. Pavelko
(Mayo Clinic)
- Michael A. Strausbauch
(Mayo Clinic)
- Yi Lin
(Mayo Clinic)
- Megan E. Grudem
(Mayo Clinic)
- Aminah Jatoi
(Mayo Clinic)
- Carolyn M. Klampe
(Mayo Clinic)
- Andrea E. Wahner-Hendrickson
(Mayo Clinic)
- S. John Weroha
(Mayo Clinic)
- Gretchen E. Glaser
(Department of Obstetrics and Gynecology)
- Amanika Kumar
(Department of Obstetrics and Gynecology)
- Carrie L. Langstraat
(Department of Obstetrics and Gynecology)
- Mary L. Solseth
(Mayo Clinic)
- Michael C. Deeds
(Mayo Clinic)
- Keith L. Knutson
(Mayo Clinic)
- Martin J. Cannon
(University of Arkansas for Medical Sciences)
Abstract
In ovarian cancer (OC), IL-17-producing T cells (Th17s) predict improved survival, whereas regulatory T cells predict poorer survival. We previously developed a vaccine whereby patient-derived dendritic cells (DCs) are programmed to induce Th17 responses to the OC antigen folate receptor alpha (FRα). Here we report the results of a single-arm open-label phase I clinical trial designed to determine vaccine safety and tolerability (primary outcomes) and recurrence-free survival (secondary outcome). Immunogenicity is also evaluated. Recruitment is complete with a total of 19 Stage IIIC-IV OC patients in first remission after conventional therapy. DCs are generated using our Th17-inducing protocol and are pulsed with HLA class II epitopes from FRα. Mature antigen-loaded DCs are injected intradermally. All patients have completed study-related interventions. No grade 3 or higher adverse events are seen. Vaccination results in the development of Th1, Th17, and antibody responses to FRα in the majority of patients. Th1 and antibody responses are associated with prolonged recurrence-free survival. Antibody-dependent cell-mediated cytotoxic activity against FRα is also associated with prolonged RFS. Of 18 patients evaluable for efficacy, 39% (7/18) remain recurrence-free at the time of data censoring, with a median follow-up of 49.2 months. Thus, vaccination with Th17-inducing FRα-loaded DCs is safe, induces antigen-specific immunity, and is associated with prolonged remission.
Suggested Citation
Matthew S. Block & Allan B. Dietz & Michael P. Gustafson & Kimberly R. Kalli & Courtney L. Erskine & Bahaaeldin Youssef & Geraldine V. Vijay & Jacob B. Allred & Kevin D. Pavelko & Michael A. Strausbau, 2020.
"Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients,"
Nature Communications, Nature, vol. 11(1), pages 1-12, December.
Handle:
RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-18962-z
DOI: 10.1038/s41467-020-18962-z
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-18962-z. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.